Spruce Biosciences, Inc. (SPRB) stock
SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$40.49−1.76 (-4.17%)
Close on Nov 17, 2026Market cap $116.37MP/E –Yield –
Spruce Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Spruce Biosciences's revenue for the twelve months ending Dec 31, 2025 was $0, down 100.0% year over year. For fiscal 2025 it was $0, down 100.0% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $4.91M | -51.3% |
| FY2023 | Dec 31, 2023 | $10.09M | – |
| FY2022 | Dec 31, 2022 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025 | Mar 31, 2025 | $0 | -100.0% |
| Q4 FY2024 | Dec 31, 2024 | $697.00K | -75.9% |
| Q3 FY2024 | Sep 30, 2024 | $602.00K | -80.4% |
| Q2 FY2024 | Jun 30, 2024 | $1.61M | -25.6% |
| Q1 FY2024 | Mar 31, 2024 | $2.00M | +1.9% |
| Q4 FY2023 | Dec 31, 2023 | $2.89M | – |
| Q3 FY2023 | Sep 30, 2023 | $3.07M | – |
| Q2 FY2023 | Jun 30, 2023 | $2.17M | – |
| Q1 FY2023 | Mar 31, 2023 | $1.96M | – |
| Q4 FY2022 | Dec 31, 2022 | $0 | – |
| Q3 FY2022 | Sep 30, 2022 | $0 | – |
| Q2 FY2022 | Jun 30, 2022 | $0 | – |
| Q1 FY2022 | Mar 31, 2022 | $0 | – |
See a number that looks wrong?